Nu-Med Plus (NUMD) Receivables (2023)
Nu-Med Plus (NUMD) reported Receivables of $3500.0 for Q1 2023.
Nu-Med Plus (NUMD) Receivables (2023) Analysis & Trends
Nu-Med Plus (NUMD) has 1 years of Receivables data on file, last reported at $3500.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.10 Bn | 176.81 Bn | 6.27 Bn | 8.21 Bn |
| 2 | Stryker | 128.79 Bn | 125.91 Bn | 3.81 Bn | 3.57 Bn |
| 3 | Medtronic | 108.97 Bn | 99.75 Bn | 6.41 Bn | 6.64 Bn |
| 4 | Boston Scientific | 68.57 Bn | 67.12 Bn | 3.61 Bn | 3.03 Bn |
| 5 | Edwards Lifesciences | 47.64 Bn | 43.97 Bn | 1.29 Bn | 973.00 Mn |
| 6 | GE HealthCare Technologies | 28.40 Bn | 26.11 Bn | 1.98 Bn | 4.50 Bn |
| 7 | Dexcom | 28.32 Bn | 27.20 Bn | 750.30 Mn | 1.11 Bn |
| 8 | Smith & Nephew | 26.94 Bn | 26.36 Bn | - | 1.55 Bn |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn | 3.80 Bn |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 3,500.00 |